•
Sep 30, 2024
Xenon Pharmaceuticals Q3 2024 Earnings Report
Xenon Pharmaceuticals reported financial results for Q3 2024 and provided a business update.
Key Takeaways
Xenon Pharmaceuticals reported a net loss of $62.8 million for the quarter ended September 30, 2024, compared to a net loss of $48.5 million for the same period in 2023. As of September 30, 2024, cash and cash equivalents and marketable securities were $803.3 million.
Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025.
Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES.
Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end.
Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025.
Xenon Pharmaceuticals
Xenon Pharmaceuticals
Forward Guidance
Xenon anticipates having sufficient cash to fund operations into 2027.